A plethora of respiratory viruses, including SARS-CoV-2, strategically manipulate the host's splicing machinery to circumvent antiviral responses. 1/
What is RNA splicing? ....a form of RNA processing in which a newly made precursor messenger RNA (pre-mRNA) transcript is transformed into a mature messenger RNA (mRNA). During splicing, introns (non-coding regions) are removed, & exons (coding regions) are joined together 2/
According to a new study, SARS-CoV-2 exploits the host splicing machinery to bolster viral replication & subvert the immune response by selectively upregulating unproductive splicing isoforms from antigen presentation & antiviral response genes. 3/
When is the Indian Covid surge driven by XBB.1.16 going to peak?
Y’day India reported >7500 cases. Early trends point the tally would def cross 8500 today. However, there is a lot of speculations on when the current peak of the surge would peak. Let’s look for the answers 1/
There are three different views:
1-According to @JPWeiland as far as weekly growth is concerned, it is already peaked. But the outbreak is still growing & the positivity rate is at the highest since Jan’21 BA.2 peak! 2/
2-As per the @MoHFW_INDIA’s ‘unusual’ claim, the COVID in India is moving towards the endemic stage. They expect the cases to rise for the next 10-12 days, and will gradually come down to become endemic 3/
I remember during my ppts for IAP’s ‘Mission Cowin’ I used to refer ORF8 an accessory protein of SARS2 that mediates immune evasion through down-regulating MHC-I 2/
ORF8 gained recognition in SARS-CoV-2 pathogenesis due to its hypervariability, secretory property, and unique structure.
Some recent papers even today describe its pivotal roles in both viral replication & immune evasion. 3/
A new study isolated two human antibodies, 12-16 & 12-19, which neutralise all SARS-CoV-2 variants tested (including XBB.1.5.). They also blocked infection in hamsters w/ BA.1 intranasally.
The fig characterises in vitro & in vivo potency and breadth of these two mAbs 1/
Structural analyses revealed both Abs targeted a conserved epitope located at the interface between NTD & subdomain 1, revealing a previously unrecognized site of vulnerability on SARS2 spike.
Antibodies 12-16 and 12-19 target a quaternary epitope between SD1 and NTD 2/
Interestingly, these Abs prevent viral receptor engagement by locking the RBD of spike in down conformation, revealing a novel mechanism of virus neutralization for non-RBD Abs. Antibody binding is incompatible w/ RBD-up state, suggesting antibody is “locked” in a down state. 3/
It has been a month when @siamosolocani 1st flagged this variant. Later, I started tracking it. We are still amid an ongoing surge, it’s time to take a stock of the situation: what we do know, what we don’t 1/
1-XBB.1.16 has succeeded in creating a new, significant surge in India after a gap of >6 months. A feat that even BA.5, BQ.1 & XBB.1.5 failed to achieve! 2/
2-XBB.1.16 definitely has got a growth advantage & more fitter than other circulating XBBs & has even replaced some other similar sublineages like XBB.1.5 & XBB.1.9 3/ @vinodscaria
Just wondering why most experts are not bothered by the rising Covid infections. They are only obsessed w/ only deaths & hospitalisations. This is a wrong narrative. If we are not able to prevent infections, we are playing in the hands of this virus 1/
You see the basic aim of any virus is to survive and transmit from one person to other. And for that it needs to infect a cell. The more the infections, the more opportunities for the virus to propagate, multiply & mutate inside the human body. 2/
Till it strikes a ‘perfect’ combination of mutations in a perfect milieu (an immunocompromised host). That may provide the virus to make more copies of itself (higher infectivity) or evade barriers to its multiplication (means immunity). 3/